BLAINJECTIONINJECTABLE
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
RETACRIT (epoetin alfa-epbx) by Pfizer. Approved for anemia, chronic kidney disease, end stage renal disease. First approved in 2018.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RETACRIT (epoetin alfa-epbx) is an injectable erythropoiesis-stimulating agent (ESA) approved by the FDA on May 15, 2018. It is indicated for the treatment of anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions requiring red blood cell stimulation. The drug works by mimicking erythropoietin to stimulate bone marrow production of red blood cells. RETACRIT represents a biosimilar alternative in a mature market dominated by branded and generic ESA competitors.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Worked on RETACRIT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.